Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, announced that it has entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercialization of its PDAOAI-enabled, GMP-compliant robotics platform.

This milestone reflects the culmination of several years of research and development efforts, resulting in an integrated platform designed to combine Oncotelic’s proprietary PDAOAI capabilities with TechForce’s robotics hardware and manufacturing expertise.

The system under development is designed to operate within GMP-regulated environments and is intended to enable automated material handling, real-time monitoring, and PDAOAI-enhanced compliance workflows across pharmaceutical manufacturing and related applications.

Key Highlights of the Commercialization:

• Integrated AI + Robotics Platform: Combines Oncotelic’s PDAOAI capabilities with TechForce’s scalable robotics systems to automate critical operational workflows.
• GMP-Compliant Design: Designed to support regulatory requirements, including data capture, audit readiness, and validation frameworks (IQ/OQ/PQ).
• Operational Efficiency & Compliance: Intended to reduce human intervention, minimizes contamination risk, and enhances process consistency through real-time monitoring and intelligent automation.
• Scalable Manufacturing Capability: Designed to leverage TechForce’s hardware expertise and manufacturing network to support commercial deployment and future growth.

“This commercialization represents a significant step forward in bridging PDAOAI and automation within regulated pharmaceutical environments,” said Dr. Vuong Trieu, chairman and Chief Executive Officer of Oncotelic. “After years of development, we are now positioned to advance our transformative solution toward commercialization that can enhance compliance, reduce operational risk, and improve efficiency across the industry.”

Ried Floco, president of TechForce Robotics, added, “Our collaboration with Oncotelic demonstrates the power of combining advanced AI with purpose-built robotics systems. With our manufacturing and deployment capabilities, we are now working toward scaling this solution for real-world applications.”

The platform supports automated material handling, integrated vision and monitoring systems, PDAOAI-Enhanced deviation detection, and generation of time-stamped documentation aligned with GMP requirements. The system is designed to continuously improve through data-driven insights and operational feedback loops.

This announcement follows the execution of a joint development, manufacturing, and licensing agreement between the parties, establishing a framework for ongoing collaboration, production scaling, and commercialization of PDAOAI-Enhanced robotic systems.